Cynvenio and Milenia Labs Enter into Exclusive Distribution Agreement for ClearID Breast Cancer Testing in Mexico

January 26, 2017 - Cynvenio Biosystems, Inc. and Milenia Labs announced a distribution agreement for Cynvenio’s ClearID® Breast Cancer. The agreement will make ClearID Breast Cancer exclusively available to customers through Milenia Labs and its network of 12 diagnostic centers in Mexico.

Cynvenio Releases Second-Generation ClearID Breast Cancer Blood Test

January 9, 2017 - Cynvenio has released its updated ClearID® Breast Cancer blood test. The new ClearID test identifies circulating tumor cell burden and detects emergent genetic alterations associated with resistance to therapy, and has been optimized to monitor patients with advanced breast cancer during initiation of therapy and at regular intervals following treatment.

Cynvenio Clinical Trial Data Supports Benefits of Multi-Template Liquid Biopsy Sequencing for Cancer Mutational Profiling

April 5, 2016 — Molecular diagnostic approaches to cancer detection and monitoring can benefit from a multiple-template strategy that analyzes DNA from circulating tumor cells (ctcDNA) and circulating cell free DNA (ccfDNA) in blood, as well as from tissue biopsies, according to new NCI-supported clinical trial published by scientists from Cynvenio Biosystems, Inc., and collaborators. The new research was published online in the journal Oncotarget.

Genome Web: Mt. Sinai Studying CTCs, ctDNA in Context of Triple Negative Breast Cancer

April 1, 2016 - Genome web article highlighting a trial by researchers at Mount Sinai to evaluate the genomic profiles of ctDNA and CTCs as well as phenotypic features of CTCs in patients with triple negative breast cancer to study the relationships between the two and how they correlate with disease. The group will use Cynvenio's LiquidBiopsy microfluidic system to isolate CTCs, ctDNA, and germline DNA.

Cynvenio Honors Triple Negative Breast Cancer Day with Clinical Trial Launch and Event at Pink Lotus Breast Center in Los Angeles

March 3, 2016 – Cynvenio Biosystems, Inc. honors Triple Negative Breast Cancer Day by launching a clinical trial for women with triple negative breast cancer (TNBC) using the company’s non-invasive liquid biopsy technology to monitor participants and identify early signs of metastasis. 

Cynvenio Announces Availability of Concordia, a New Cell-free DNA Purification Upgrade for its LiquidBiopsy Whole Blood Enrichment Platform

February 10, 2016 – Cynvenio announces the availability of the Concordia™ cell-free DNA (cfDNA) purification sample preparation upgrade for its multi-template analysis LiquidBiopsy® platform. When coupled with Thermo Fisher Scientific’s Ion Torrent™ next-generation sequencing (NGS) systems, Cynvenio’s workflow provides a comprehensive molecular characterization of tumor cell DNA for cancer research samples from a standard blood draw.

Cynvenio and ATGen Open Recruitment for New LiquidBiopsy Clinical Research Study in Triple Negative Breast Cancer

December 28, 2015 – Cynvenio Biosystems, Inc. and ATGen Global, a Korea-based biotech company, announced the launch of a pilot study to evaluate a new method for early detection of cancer in women who have completed treatment for triple-negative breast cancer (TNBC) and show no radiographic signs of metastases.

Cynvenio Biosystems Announces Collaboration with University of Southern Denmark for Cancer Clinical Trials

December 2, 2015 – Cynvenio announces that it has entered into a strategic collaboration with the Institute of Regional Health Research for the Region of Southern Denmark at the University of Southern Denmark to conduct a wide array of clinical cancer trials using Cynvenio’s Triple Play LiquidBiopsy® platform.

Cynvenio Biosystems and ATGen Announce Strategic Partnership to bring NK Vue Natural Killer Cell Test to US Market

September 29, 2015 – Cynvenio Biosystems, Inc. and ATGen Global, a private biotech company in Korea that manufactures and supplies a wide array of recombinant proteins and antibodies worldwide, announces the companies a collaborative partnership to bring ATGen’s NK Vue™ test to the US market.